3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The Actin Bundling Protein Fascin-1 as an ACE2-Accessory Protein

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We have previously shown that angiotensin-converting enzyme 2 (ACE2), an enzyme counterbalancing the deleterious effects of angiotensin type 1 receptor activation by production of vasodilatory peptides Angiotensin (Ang)-(1–9) and Ang-(1–7), is internalized and degraded in lysosomes following chronic Ang-II treatment. However, the molecular mechanisms involved in this effect remain unknown. In an attempt to identify the accessory proteins involved in this effect, we conducted a proteomic analysis in ACE2-transfected HEK293T cells. A single protein, fascin-1, was found to differentially interact with ACE2 after Ang-II treatment for 4 h. The interactions between fascin-1 and ACE2 were confirmed by confocal microscopy and co-immunoprecipitation. Overexpression of fascin-1 attenuates the effects of Ang-II on ACE2 activity. In contrast, downregulation of fascin-1 severely decreased ACE2 enzymatic activity. Interestingly, in brain homogenates from hypertensive mice, we observed a significant reduction of fascin-1, suggesting that the levels of this protein may change in cardiovascular diseases. In conclusion, we identified fascin-1 as an ACE2-accessory protein, interacting with the enzyme in an Ang-II dependent manner and contributing to the regulation of enzyme activity.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

          Coronavirus disease 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus strain disease, has recently emerged in China and rapidly spread worldwide. This novel strain is highly transmittable and severe disease has been reported in up to 16% of hospitalized cases. More than 600,000 cases have been confirmed and the number of deaths is constantly increasing. COVID-19 hospitalized patients, especially those suffering from severe respiratory or systemic manifestations, fall under the spectrum of the acutely ill medical population, which is at increased venous thromboembolism risk. Thrombotic complications seem to emerge as an important issue in patients infected with COVID-19. Preliminary reports on COVID-19 patients’ clinical and laboratory findings include thrombocytopenia, elevated D-dimer, prolonged prothrombin time, and disseminated intravascular coagulation. As the pandemic is spreading and the whole picture is yet unknown, we highlight the importance of coagulation disorders in COVID-19 infected patients and review relevant data of previous coronavirus epidemics caused by the severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV).
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor–Dependent MechanismNovelty and Significance

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century

              At the beginning of the 21st century, a new deadly infectious disease known as severe acute respiratory syndrome (SARS) was recognized as a global public health threat. Subsequently, ten years after the initial SARS cases occurred in 2002, new cases of another atypical respiratory disease caused worldwide concern. This disease became known as Middle East respiratory syndrome (MERS) and was even more lethal than SARS. Currently, history has repeated itself with the emergence of a new Chinese epidemic at the end of 2019. For this respiratory disease, called COVID-19, a novel coronavirus (SARS-CoV-2) was identified as the etiologic agent. In sum, SARS, MERS and COVID-19 are caused by recently discovered coronaviruses that cause flu-like illnesses, but with a clinical outcome that tends to be more severe. As a result of the current importance of coronaviruses in global public health, we conducted a review to summarize and update, above all, the epidemiological historical aspects of the three major diseases in humans caused by coronaviral infection. Electronic supplementary material The online version of this article (10.1007/s00705-020-04628-0) contains supplementary material, which is available to authorized users.
                Bookmark

                Author and article information

                Contributors
                Catalin.Filipeanu@Howard.edu
                Journal
                Cell Mol Neurobiol
                Cell. Mol. Neurobiol
                Cellular and Molecular Neurobiology
                Springer US (New York )
                0272-4340
                1573-6830
                31 August 2020
                : 1-9
                Affiliations
                [1 ]GRID grid.257127.4, ISNI 0000 0001 0547 4545, Department of Pharmacology, College of Medicine, , Howard University, ; 520 W St., NW, Washington, DC 20059 USA
                [2 ]GRID grid.279863.1, ISNI 0000 0000 8954 1233, Department of Biochemistry and Molecular Biology, , Louisiana State University Health Sciences Center, ; New Orleans, LA 70112 USA
                [3 ]GRID grid.279863.1, ISNI 0000 0000 8954 1233, Department of Pharmacology & Experimental Therapeutics, , Louisiana State University Health Sciences Center, ; New Orleans, LA 70112 USA
                [4 ]GRID grid.255364.3, ISNI 0000 0001 2191 0423, Department of Pharmacology and Toxicology, , Brody School of Medicine at East Carolina University, ; 600 Moye Blvd, Greenville, NC 27834 USA
                [5 ]GRID grid.279863.1, ISNI 0000 0000 8954 1233, Cardiovascular Center of Excellence, , Louisiana State University Health Sciences Center, ; New Orleans, LA 70112 USA
                [6 ]GRID grid.417056.1, ISNI 0000 0004 0419 6004, Southeast Louisiana Veterans Health Care Systems, ; New Orleans, LA 70119 USA
                Author information
                http://orcid.org/0000-0002-4256-4547
                http://orcid.org/0000-0002-5601-0430
                http://orcid.org/0000-0002-5359-3087
                http://orcid.org/0000-0001-9937-1589
                http://orcid.org/0000-0001-7290-0786
                http://orcid.org/0000-0002-7298-9327
                Article
                951
                10.1007/s10571-020-00951-x
                7456754
                3709c40e-d2a7-4195-9b96-f8df932a7565
                © Springer Science+Business Media, LLC, part of Springer Nature 2020

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 17 June 2020
                : 20 August 2020
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000002, National Institutes of Health;
                Award ID: R01HL150592-01
                Award ID: R01HL150592-01
                Award ID: P30GM106392
                Award ID: P30GM106392
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/10000073, U.S. Department of Veterans Affairs;
                Award ID: BX004294
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100012365, Howard University;
                Award ID: Bridge Funds
                Award Recipient :
                Categories
                Original Research

                Neurosciences
                angiotensin-converting enzyme 2,fascin-1,actin bundling protein,internalization,angiotensin type 1 receptor

                Comments

                Comment on this article